{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:02:12Z","timestamp":1790928132015,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04142-2","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T15:18:49Z","timestamp":1764947929000},"page":"1586-1594","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A comprehensive review of sex differences in the clinical outcomes to immunotherapy on solid tumors"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7368-2263","authenticated-orcid":false,"given":"Juan Carlos","family":"Redondo-Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4606-2316","authenticated-orcid":false,"given":"Luis","family":"Posado-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Corvo-F\u00e9lix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Bellido Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2918-6084","authenticated-orcid":false,"given":"I\u00f1igo San","family":"Miguel-Arregui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7363-6454","authenticated-orcid":false,"given":"Emilio","family":"Fonseca-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1992-6105","authenticated-orcid":false,"given":"Alejandro","family":"Olivares-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6443-0585","authenticated-orcid":false,"given":"Edel","family":"del Barco-Morillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"7","key":"4142_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ccell.2022.06.005","volume":"40","author":"L Pala","year":"2022","unstructured":"Pala L, Depas T, Catania C, Giaccone G, Mantovani A, Minucci S, et al. Sex and cancer immunotherapy: current understanding and challenges. Cancer Cell. 2022;40(7):695\u2013700.","journal-title":"Cancer Cell"},{"issue":"18","key":"4142_CR2","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.3390\/molecules24183214","volume":"24","author":"S Wang","year":"2019","unstructured":"Wang S, Cowley LA, Liu XS. Sex differences in cancer immunotherapy efficacy, biomarkers and therapeutic strategy. Molecules. 2019;24(18):3214.","journal-title":"Molecules"},{"issue":"7","key":"4142_CR3","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3390\/biomedicines8070232","volume":"8","author":"A Irelli","year":"2020","unstructured":"Irelli A, Sirufo MM, D\u2019Ugo C, Ginaldi L, De Martinis M. Sex and gender influences on cancer immunotherapy response. Biomedicines. 2020;8(7):232.","journal-title":"Biomedicines"},{"issue":"3","key":"4142_CR4","doi-asserted-by":"publisher","first-page":"000344","DOI":"10.1136\/esmoopen-2018-000344","volume":"3","author":"JA Pinto","year":"2018","unstructured":"Pinto JA, Vallejos CS, Raez LE, Mas LA, Ruiz R, Torres-Roman JS, et al. Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy? ESMO Open. 2018;3(3):000344.","journal-title":"ESMO Open"},{"issue":"59","key":"4142_CR5","doi-asserted-by":"publisher","first-page":"99336","DOI":"10.18632\/oncotarget.22242","volume":"8","author":"A Botticelli","year":"2017","unstructured":"Botticelli A, Onesti CE, Zizzari I, Cerbelli B, Sciattella P, Occhipinti M, et al. The sexist behaviour of immune checkpoint inhibitors in cancer therapy? Oncotarget. 2017;8(59):99336\u201346.","journal-title":"Oncotarget"},{"issue":"12","key":"4142_CR6","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3390\/jcm7120542","volume":"7","author":"A Grassadonia","year":"2018","unstructured":"Grassadonia A, Sperduti I, Vici P, Iezzi L, Brocco D, Gamucci T, et al. Effect of gender on the outcome of patients receiving immune checkpoint inhibitors for advanced cancer. J Clin Med. 2018;7(12):542.","journal-title":"J Clin Med"},{"issue":"6","key":"4142_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","volume":"19","author":"F Conforti","year":"2018","unstructured":"Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, et al. Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis. Lancet Oncol. 2018;19(6):737\u201346.","journal-title":"Lancet Oncol"},{"issue":"4","key":"4142_CR8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jamaoncol.2018.5904","volume":"5","author":"CJD Wallis","year":"2019","unstructured":"Wallis CJD, Butaney M, Satkunasivam R, Freedland SJ, Patel SP, Hamid O, et al. Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers. JAMA Oncol. 2019;5(4):529.","journal-title":"JAMA Oncol"},{"issue":"11","key":"4142_CR9","doi-asserted-by":"publisher","first-page":"7379","DOI":"10.3390\/curroncol31110544","volume":"31","author":"SF Cohen","year":"2024","unstructured":"Cohen SF, Cruiziat D, Naimer J, Cohen V, Kasymjanova G, Spatz A, et al. Sex-related differences in immunotherapy outcomes of patients with advanced non-small cell lung cancer. Curr Oncol. 2024;31(11):7379\u201389.","journal-title":"Curr Oncol"},{"issue":"21","key":"4142_CR10","doi-asserted-by":"publisher","first-page":"11942","DOI":"10.3390\/ijms222111942","volume":"22","author":"T Vaval\u00e0","year":"2021","unstructured":"Vaval\u00e0 T, Catino A, Pizzutilo P, Longo V, Galetta D. Gender differences and immunotherapy outcome in advanced lung cancer. Int J Mol Sci MDPI. 2021;22(21):11942.","journal-title":"Int J Mol Sci MDPI"},{"issue":"5","key":"4142_CR11","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41568-024-00680-z","volume":"24","author":"T Xiao","year":"2024","unstructured":"Xiao T, Lee J, Gauntner TD, Velegraki M, Lathia JD, Li Z. Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications. Nat Rev Cancer. 2024;24(5):338\u201355.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"4142_CR12","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1016\/S1470-2045(18)30483-2","volume":"19","author":"JL McQuade","year":"2018","unstructured":"McQuade JL, Daniel CR, Hess KR, Davies MA. Sex as a predictor of response to cancer immunotherapy. Lancet Oncol. 2018;19(8):e376.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4142_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13293-022-00469-5","volume":"13","author":"J Ma","year":"2022","unstructured":"Ma J, Yao Y, Tian Y, Chen K, Liu B. Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang. Biol Sex Differ. 2022;13(1):58.","journal-title":"Biol Sex Differ"},{"issue":"1","key":"4142_CR14","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/s41467-020-15679-x","volume":"11","author":"Y Ye","year":"2020","unstructured":"Ye Y, Jing Y, Li L, Mills GB, Diao L, Liu H, et al. Sex-associated molecular differences for cancer immunotherapy. Nat Commun. 2020;11(1):1779.","journal-title":"Nat Commun"},{"issue":"8","key":"4142_CR15","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/jnci\/djz096","volume":"111","author":"LM Colli","year":"2019","unstructured":"Colli LM, Morton LM, Chanock SJ. Sex-Related Effect on Immunotherapy Response: Implications and Opportunities. J Natl Cancer Inst. 2019;111(8):749\u201350.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"4142_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2174\/1568009622666220831142452","volume":"25","author":"E Caliman","year":"2025","unstructured":"Caliman E, Petrella MC, Rossi V, Mazzoni F, Grosso AM, Fancelli S, et al. Gender matters. sex-related differences in immunotherapy outcome in patients with non-small cell lung cancer. Curr Cancer Drug Targets. 2025;25(1):64\u201371.","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"4142_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13293-020-00301-y","volume":"11","author":"SL Klein","year":"2020","unstructured":"Klein SL, Morgan R. The impact of sex and gender on immunotherapy outcomes. Biol Sex Differ. 2020;11(1):24.","journal-title":"Biol Sex Differ"},{"issue":"7","key":"4142_CR18","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3390\/cancers17071054","volume":"17","author":"J Canzian","year":"2025","unstructured":"Canzian J, Conforti F, Jacobs F, Benvenuti C, Gaudio M, Gerosa R, et al. Sex-related differences in immunotherapy toxicities: insights into dimorphic responses. Cancers (Basel). 2025;17(7):1054.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"4142_CR19","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1002\/1878-0261.13203","volume":"16","author":"J Han","year":"2022","unstructured":"Han J, Yang Y, Li X, Wu J, Sheng Y, Qiu J, et al. Pan-cancer analysis reveals sex-specific signatures in the tumor microenvironment. Mol Oncol. 2022;16(11):2153.","journal-title":"Mol Oncol"},{"key":"4142_CR20","first-page":"4433","volume-title":"Cancers","author":"G Suay","year":"2023","unstructured":"Suay G, Garcia-Ca\u00f1averas JC, Aparisi F, Lahoz A, Juan-Vidal O. Sex Differences in the Efficacy of Immune Checkpoint Inhibitors in Neoadjuvant Therapy of Non-Small Cell Lung Cancer A Meta-Analysis. In: Cancers. Switzerland: Multidisciplinary Digital Publishing Institute (MDPI); 2023. p. 4433."},{"key":"4142_CR21","doi-asserted-by":"publisher","first-page":"175883592413069","DOI":"10.1177\/17588359241306940","volume":"16","author":"R Leporati","year":"2024","unstructured":"Leporati R, Auclin \u00c9, Morch\u00f3n D, Ferriol-Galm\u00e9s M, Laguna JC, Gorria T, et al. Sex differences in patients with non-small cell lung cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review. Ther Adv Med Oncol. 2024;16:17588359241306940.","journal-title":"Ther Adv Med Oncol"},{"issue":"13","key":"4142_CR22","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1200\/JCO.21.02377","volume":"40","author":"JM Unger","year":"2022","unstructured":"Unger JM, Vaidya R, Albain KS, Leblanc M, Minasian LM, Gotay CC, et al. Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials. J Clin Oncol. 2022;40(13):1474\u201386.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4142_CR23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","volume":"36","author":"J Larkin","year":"2018","unstructured":"Larkin J, Minor D, D\u2019Angelo S, Neyns B, Smylie M, Miller WH, et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in checkmate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol. 2018;36(4):383\u201390.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4142_CR24","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","volume":"17","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17(11):1558\u201368.","journal-title":"Lancet Oncol"},{"issue":"26","key":"4142_CR25","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, O\u2019Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517\u201326.","journal-title":"N Engl J Med"},{"issue":"5","key":"4142_CR26","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","volume":"31","author":"A Ribas","year":"2013","unstructured":"Ribas A, Kefford R, Marshall MA, Punt CJA, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31(5):616\u201322.","journal-title":"J Clin Oncol"},{"issue":"30","key":"4142_CR27","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1200\/JCO.2016.71.7629","volume":"35","author":"R Govindan","year":"2017","unstructured":"Govindan R, Szczesna A, Ahn MJ, Schneider CP, Mella PFG, Barlesi F, et al. Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J Clin Oncol. 2017;35(30):3449\u201357.","journal-title":"J Clin Oncol"},{"issue":"25","key":"4142_CR28","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","volume":"376","author":"DP Carbone","year":"2017","unstructured":"Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376(25):2415\u201326.","journal-title":"N Engl J Med"},{"issue":"11","key":"4142_CR29","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/S1470-2045(18)30673-9","volume":"19","author":"F Barlesi","year":"2018","unstructured":"Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol. 2018;19(11):1468\u201379.","journal-title":"Lancet Oncol"},{"issue":"17","key":"4142_CR30","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627\u201339.","journal-title":"N Engl J Med"},{"issue":"10027","key":"4142_CR31","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, P\u00e9rez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. The Lancet. 2016;387(10027):1540\u201350.","journal-title":"The Lancet"},{"issue":"2","key":"4142_CR32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer. N Engl J Med. 2015;373(2):123\u201335.","journal-title":"N Engl J Med"},{"issue":"19","key":"4142_CR33","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"10066","key":"4142_CR34","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255\u201365.","journal-title":"Lancet"},{"issue":"24","key":"4142_CR35","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342\u201350.","journal-title":"N Engl J Med"},{"issue":"21","key":"4142_CR36","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, G\u00fcm\u00fc\u015f M, Mazi\u00e8res J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040\u201351.","journal-title":"N Engl J Med"},{"issue":"22","key":"4142_CR37","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"31","key":"4142_CR38","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1200\/JCO.2016.67.6601","volume":"34","author":"M Reck","year":"2016","unstructured":"Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34(31):3740\u20138.","journal-title":"J Clin Oncol"},{"issue":"23","key":"4142_CR39","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220\u20139.","journal-title":"N Engl J Med"},{"issue":"19","key":"4142_CR40","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"28","key":"4142_CR41","doi-asserted-by":"publisher","first-page":"v628","DOI":"10.1093\/annonc\/mdx440.040","volume":"1","author":"EE Cohen","year":"2017","unstructured":"Cohen EE, Harrington KJ, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, et al. Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R\/M HNSCC): phase 3 KEYNOTE-040 trial. Ann Oncol. 2017;1(28):v628.","journal-title":"Ann Oncol"},{"issue":"19","key":"4142_CR42","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856\u201367.","journal-title":"N Engl J Med"},{"issue":"11","key":"4142_CR43","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326.","journal-title":"N Engl J Med"},{"issue":"10111","key":"4142_CR44","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461\u201371.","journal-title":"Lancet"},{"issue":"9","key":"4142_CR45","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","volume":"18","author":"M Maio","year":"2017","unstructured":"Maio M, Scherpereel A, Calabr\u00f2 L, Aerts J, Perez SC, Bearz A, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18(9):1261\u201373.","journal-title":"Lancet Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04142-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04142-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04142-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:03:19Z","timestamp":1776769399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04142-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["4142"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04142-2","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participation"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}